A combined dual-chamber typhoid/hepatitis A vaccine as a booster dose in hepatitis A primed adults.
Vivaxim is a combined hepatitis A/typhoid fever vaccine (HA/Vi) licensed for vaccination of travellers, but long-term protection against hepatitis A requires two immunisations at least 6 months apart. A randomised, controlled study was performed in 116 healthy adults primed with hepatitis A vaccine (Avaxim) to compare immune responses to HA/Vi and Avaxim given as booster doses 6 months later. Both vaccines elicited marked booster responses achieving antibody geometric mean titres (GMTs) of 4576 and 3760 mIU/ml in the HA/Vi and Avaxim groups, respectively. Although twice as frequent in the HA/Vi group, local reactions (mostly pain) were mainly mild and transient, probably reflecting the larger volume injected (1ml). Vivaxim offers a convenient means of administering both HA and typhoid fever vaccines in subjects already primed for hepatitis A.
Beran
Jirí
J
Vaccination and Travel Medicine Centre, Poliklinika II, Bratri Stefanu 895, 50003 Hradec Králové, Czech Republic. jiri.beran@vakcinace.cz
Chlibek
Roman
R
Weber
Françoise
F
D000293:Adolescent; D000328:Adult; D005260:Female; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D017957:Hepatitis A Virus, Human / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008297:Male; D014436:Typhoid-Paratyphoid Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated
D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D014436:Typhoid-Paratyphoid Vaccines; D017778:Vaccines, Combined; D015164:Vaccines, Inactivated